Avyxa Holdings Company Profile
✉ Email this page to a colleague
What is the competitive landscape for AVYXA HOLDINGS, and when can generic versions of AVYXA HOLDINGS drugs launch?
AVYXA HOLDINGS has five approved drugs.
There are three US patents protecting AVYXA HOLDINGS drugs.
There are eight patent family members on AVYXA HOLDINGS drugs in five countries and fourteen supplementary protection certificates in seven countries.
Summary for Avyxa Holdings
| International Patents: | 8 |
| US Patents: | 3 |
| Tradenames: | 5 |
| Ingredients: | 5 |
| NDAs: | 5 |
Drugs and US Patents for Avyxa Holdings
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Avyxa Holdings | DOCIVYX | docetaxel | SOLUTION;INTRAVENOUS | 215813-003 | Nov 22, 2022 | RX | Yes | Yes | 10,398,785 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Avyxa Holdings | DOCIVYX | docetaxel | SOLUTION;INTRAVENOUS | 215813-002 | Nov 22, 2022 | RX | Yes | Yes | 10,398,785 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Avyxa Holdings | CYCLOPHOSPHAMIDE | cyclophosphamide | SOLUTION;INTRAVENOUS | 210852-001 | Jun 7, 2023 | RX | Yes | Yes | 11,382,923 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Avyxa Holdings | CYCLOPHOSPHAMIDE | cyclophosphamide | SOLUTION;INTRAVENOUS | 210852-002 | Jun 7, 2023 | RX | Yes | Yes | 11,382,923 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Avyxa Holdings Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2016149162 | ⤷ Subscribe |
| Japan | 2018512395 | ⤷ Subscribe |
| China | 111728941 | ⤷ Subscribe |
| China | 111714449 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Avyxa Holdings Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2785706 | 2020C/516 | Belgium | ⤷ Subscribe | PRODUCT NAME: AKYNZEO - FOSNETUPITANT/PALONOSETRON; AUTHORISATION NUMBER AND DATE: EU/1/15/1001 20200318 |
| 2785706 | LUC00158 | Luxembourg | ⤷ Subscribe | PRODUCT NAME: AKYNZEO - FOSNETUPITANT/PALONOSETRON; AUTHORISATION NUMBER AND DATE: EU/1/15/1001 20200318 |
| 0432677 | 7/2005 | Austria | ⤷ Subscribe | PRODUCT NAME: PEMETREXED UND DESSEN PHARMAZEUTISCH ANNAHMBAREN SALZE; REGISTRATION NO/DATE: EU/1/04/290/001 20040920 |
| 0138504 | 2004C/004 | Belgium | ⤷ Subscribe | PRODUCT NAME: FULVESTRANT; REGISTRATION NO/DATE: EU/1/03/269/001 20040311 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
